Liver Cirrhosis: Clinical Trials

1,517 trials for Liver Cirrhosis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

622 completed, 378 unknown, 197 recruiting, 101 not yet recruiting. 384 Not applicable, 232 Phase 2, 144 Phase 3, 119 Phase 1, 105 Phase 4.

By phase and status

PhaseTrialsStatus
Not applicable384Completed 139, Unknown 112, Recruiting 52, Not yet recruiting 28, Terminated 25, Active not recruiting 13, Withdrawn 9, Enrolling by invitation 6
Phase 2232Completed 111, Unknown 40, Terminated 31, Recruiting 24, Not yet recruiting 11, Withdrawn 7, Active not recruiting 6, Enrolling by invitation 1, Suspended 1
Phase 3144Completed 64, Unknown 26, Recruiting 22, Terminated 14, Active not recruiting 7, Not yet recruiting 6, Withdrawn 3, Enrolling by invitation 1, Suspended 1
Phase 1119Completed 66, Unknown 28, Recruiting 8, Not yet recruiting 5, Terminated 5, Withdrawn 5, Active not recruiting 1, Suspended 1
Phase 4105Completed 38, Unknown 35, Recruiting 10, Terminated 9, Active not recruiting 6, Not yet recruiting 3, Withdrawn 3, Enrolling by invitation 1
Early Phase 113Completed 6, Unknown 6, Active not recruiting 1

Follow Liver Cirrhosis: new trials by email Literature Review of Liver Cirrhosis trials Research Report on Liver Cirrhosis

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Blood Flow Restriction Training After TIPS Placement in Liver Cirrhosis
Blood-flow restriction training (BFRT) - Liver Cirrhosis, TIPS Insertion
Not applicableNot yet recruitingGerman Diabetes Center302027-01-022026-11-13
Fiber-Optic Navigation During TIPS Creation: A Prospective Pilot Study
Fiber-Optic Navigation System - Liver Cirrhosis, Refractory Ascites
Not applicableNot yet recruitingMedical University Innsbruck302027-01-012026-03-13
Pomegranate Dietary Supplements in AUD and ALD
Pomegranate Dietary Ssupplement - Alcohol Use Disorder, Alcohol-associated Liver Disease
Not yet recruitingUniversity of Louisville1442027-01-012026-07-24
Inflammatory and Neuroimmune Guided Investigation of Underlying Fatigue in Patients With Cirrhosis
Cirrhosis Alcoholic, Fatigue Symptom
Not yet recruitingKing's College London502027-01-012026-10-27
Within-Session Repeatability of EUS-Guided Portal Pressure Gradient Measurement
Repeated EUS-Guided Portal Pressure Gradient Measurement - Portal Hypertension, Chronic Liver Disease
Not yet recruitingUniversity Hospital Muenster1502027-01-012026-11-13
Prickly Pear Pulp Powder Along With an Anti-inflammatory Diet in Patients Having Liver Fibrosis
Experimental, Placebo - Lipid Profile, Blood Glucose
Not applicableNot yet recruitingUniversity of Lahore1202026-12-152026-10-29
Study to Evaluate ALN-CIDEB in Adults With Fibrotic Alcohol-Associated Liver Disease (ALD)
ALN-CIDEB, Placebo - Alcohol-Associated Liver Disease, ALD
Phase 2Not yet recruitingRegeneron Pharmaceuticals1202026-12-092026-11-12
Erlotinib for Hepatocellular Carcinoma Chemoprevention
erlotinib hydrochloride, Placebo - Cirrhosis, Liver, Advanced Liver Fibrosis
Phase 2Not yet recruitingUniversity of Texas Southwestern Medical Center602026-12-012026-06-24
Daridorexant for Sleep Disturbance in Adults With Liver Cirrhosis
Daridorexant, Placebo - Liver Cirrhosis, Sleep Disturbance
Phase 4Not yet recruitingWang Fengmei1802026-12-012026-11-17
Isocaloric Navy-Bean Substitution in Adults With MASLD
Dietary Supplement/Behavioral: Navy Bean-Rich Diet, Habitual Diet (Control) - Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Liver Fibrosis
Not applicableNot yet recruitingIcahn School of Medicine at Mount Sinai402026-11-252026-11-10
Prospective AI-SC Trial
Artificial Intelligence Selection Committee (AI-SC) - Liver Cirrhosis
Not yet recruitingUniversity Health Network, Toronto2002026-11-132026-11-10
A Study of Fatigue, Itching and Daily Activities in People With Primary Biliary Cholangitis Starting Elafibranor
Elafibranor - Primary Biliary Cholangitis (PBC)
Not yet recruitingIpsen502026-11-022026-10-30
Different Treatment Frequencies for Hepatic Fibrosis Due to Schistosomiasis
Praziquantel 40 mg/kg per dose given once annually, Praziquantel 40 mg/kg given three times per year - Schistosomiasis, Schistosoma Mansoni
Phase 2 / Phase 3Not yet recruitingRhode Island Hospital6002026-11-012026-08-12
Nemolizumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus
Nemolizumab-ilto - Chronic Hepatic Pruritus, Cholestatic Liver Disease
Phase 2Not yet recruitingMayo Clinic152026-11-012026-09-28
Predicting Response and Exposure Changes in Cirrhosis for Effectiveness
Five-Drug CYP Probe Cocktail - Liver Cirrhosis
Not applicableNot yet recruitingAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)452026-11-012026-08-11
Lifestyle, Dietary Patterns, and Cardiometabolic Risk in Metabolic Dysfunction-Associated Steatotic Liver Disease Among People Living With HIV
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), HIV Infections
Not yet recruitingAssiut University2502026-11-012026-10-06
The Value of Spleen Thickness and Spleen Diameter for Gastroesophageal Varices Diagnosis in Compensated Cirrhosis
spleen diameter, spleen thickness, esophagogastroduodenoscopy (EGD) - Liver Cirrhosis, Gastroesophageal Varices
RecruitingFifth Affiliated Hospital, Sun Yat-Sen University3642026-10-282026-11-06
Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
ALN-CIDEB, Placebo - Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD
Phase 3RecruitingRegeneron Pharmaceuticals15002026-10-282026-11-17
J-LINX: Japan LINerixibat eXtension Study
Linerixibat - Pruritus
Phase 3Not yet recruitingGlaxoSmithKline402026-10-092026-10-06
Endohepatology-Based Reclassification of Treatment Indication in High-Risk MASLD
Non-invasive MASLD and portal hypertension assessment, Single-session endohepatology assessment - Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis
RecruitingUniversity Hospital Muenster5002026-10-052026-10-20

Showing 20 of 1517. Sign in to see all of them.

Narrower conditions

Liver Cirrhosis, Biliary (214)  ·  Fibrosis (185)  ·  Non-alcoholic Fatty Liver Disease (139)  ·  Hypertension, Portal (123)  ·  Carcinoma, Hepatocellular (101)  ·  Liver Diseases (98)  ·  Fatty Liver (76)  ·  Hepatic Encephalopathy (60)  ·  Ascites (55)  ·  Hepatitis C (55)  ·  Hepatitis B (46)  ·  Liver Cirrhosis, Alcoholic (45)  ·  Esophageal and Gastric Varices (37)  ·  Liver Neoplasms (35)

Broader conditions

Pathological Conditions, Signs and Symptoms (1517)  ·  Pathologic Processes (1514)  ·  Digestive System Diseases (1506)  ·  Liver Diseases (1419)  ·  Fibrosis (1332)  ·  Biliary Tract Diseases (221)  ·  Bile Duct Diseases (220)  ·  Cholestasis, Intrahepatic (214)  ·  Cholestasis (201)  ·  Nutritional and Metabolic Diseases (168)  ·  Infections (167)  ·  Hepatitis (159)  ·  Virus Diseases (144)  ·  Blood-Borne Infections (136)

Interventions

Ursodeoxycholic Acid (29)  ·  Rifaximin (21)  ·  Portasystemic Shunt, Transjugular Intrahepatic (19)  ·  Albumins (17)  ·  Standard of Care (17)  ·  Blood Specimen Collection (14)  ·  Carvedilol (14)  ·  obeticholic acid (13)  ·  Fenofibrate (12)  ·  Propranolol (12)  ·  Ribavirin (12)  ·  Terlipressin (11)  ·  entecavir (11)  ·  Lactulose (10)  ·  Probiotics (10)

Sponsors

Institute of Liver and Biliary Sciences, India (51)  ·  Assiut University (32)  ·  Assistance Publique - Hôpitaux de Paris (22)  ·  Beijing Friendship Hospital (17)  ·  Post Graduate Institute of Medical Education and Research, Chandigarh (17)  ·  Air Force Military Medical University, China (16)  ·  Gilead Sciences (15)  ·  Seoul National University Hospital (15)  ·  Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran (13)  ·  University of Aarhus (13)  ·  Xijing Hospital of Digestive Diseases (13)  ·  West China Hospital (12)  ·  AstraZeneca (11)  ·  Intercept Pharmaceuticals (11)  ·  Mayo Clinic (11)

Countries

United States (318)  ·  China (260)  ·  France (128)  ·  Germany (114)  ·  United Kingdom (112)  ·  Spain (106)  ·  Italy (102)  ·  India (85)  ·  Canada (84)  ·  South Korea (75)  ·  Belgium (60)  ·  Egypt (53)  ·  Denmark (50)  ·  Mexico (41)  ·  Netherlands (39)

Top investigators

Guo-Qing Jiang, MD (8)  ·  Kiminori Kimura, MD (5)  ·  Li Yang, MD (5)  ·  Shiyao Chen, Professor (5)  ·  Guohong Han, PhD & MD (4)  ·  Hong You, Doctor (4)  ·  Ming-Chih Hou, MD (4)  ·  Xiaolong Qi, M.D. (4)  ·  Aldo Torre Delgadillo, M.D. M.Sc (3)

Results publications

PMID 37467180, PMID 25543678, PMID 33460002, PMID 21836029, PMID 16020491, PMID 16306522, PMID 16799972, PMID 19208350, PMID 25638527, PMID 26644276, PMID 27786365, PMID 28249726, PMID 28506905, PMID 29990488, PMID 30180806, PMID 31342529, PMID 31394282, PMID 32860184, PMID 33307033, PMID 33657443, PMID 34843068, PMID 35120736, PMID 36750244, PMID 37396307, PMID 37953500, PMID 37973887, PMID 38780109, PMID 39373164, PMID 40439725, PMID 40751304, PMID 41680079, PMID 42438428, PMID 10051462, PMID 10075602, PMID 10102814, PMID 10343210, PMID 10343514, PMID 10347106, PMID 10643630, PMID 10655252, PMID 10922085, PMID 10922086, PMID 10934332, PMID 11095334, PMID 1109749, PMID 11267312, PMID 11343232, PMID 11588440, PMID 11851836, PMID 11876689

NIH funding

2019 (7), 2016 (6), 2023 (6), 2014 (3), 2017 (3), 2018 (3), 2005 (2), 2009 (2), 2015 (2), R01AG006244 (2), U24DK130164 (2), 2008 (1), 5UL1TR002373-04 (1), I01CX002436 (1), I50HX002903 (1)